Leyden Labs Raises $70M to Advance Mucosal Protection Platform

  • Leyden Labs has raised $70 million to advance its Mucosal Protection Platform, which uses intranasally administered antibodies to protect against respiratory viruses.
  • The funding round was co-led by ClavystBio and Polaris Partners, with additional backing from several venture investors.

Leyden Labs has announced the successful completion of a $70 million funding round aimed at furthering the development of its Mucosal Protection Platform. This non-vaccine approach focuses on the use of broadly protective intranasal antibodies to shield individuals from the threat of respiratory viruses such as influenza and coronaviruses.

The investment was co-led by ClavystBio, a life sciences venture firm established by Temasek, and Polaris Partners, with participation from other significant investors including Qiming Venture Partners, GV (formerly Google Ventures), and Softbank Vision Fund 2, among others. This funding will support the continued advancement of the company’s pipeline, which includes its PanFlu candidate, a nasal spray designed to prevent influenza infections.

Koenraad Wiedhaup, co-founder and CEO of Leyden Labs, stated, “This strong support from investors validates our approach to providing broad, universal protection against current and future viral outbreaks.” The funding will enable the initiation of human efficacy studies for the PanFlu nasal spray and further progress in the company’s broader research on respiratory virus protection.

Additionally, Leyden Labs has announced the acquisition of CoV Biotechnology Pte. Ltd., a Singapore-based company. This acquisition brings further expertise in emerging infectious diseases and enhances the company’s pandemic preparedness efforts.

The funding round positions Leyden Labs to accelerate its mission of providing universal protection against viral infections, with a focus on combating respiratory viruses, including those that may arise in future pandemics. The company will present its latest developments at the upcoming JP Morgan Annual Healthcare Conference.

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.